204 related articles for article (PubMed ID: 24673885)
1. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
Stahl SM
CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
[TBL] [Abstract][Full Text] [Related]
2. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
Ashby CR; Kehne JH; Bartoszyk GD; Renda MJ; Athanasiou M; Pierz KA; Seyfried CA
Eur J Pharmacol; 2013 Aug; 714(1-3):359-65. PubMed ID: 23872377
[TBL] [Abstract][Full Text] [Related]
5. Vilazodone (Viibryd)--a new antidepressant.
Med Lett Drugs Ther; 2011 Jul; 53(1368):53-4. PubMed ID: 21738107
[TBL] [Abstract][Full Text] [Related]
6. A new antidepressant.
Glazer WM
Behav Healthc; 2011 Sep; 31(6):39-40. PubMed ID: 22026116
[No Abstract] [Full Text] [Related]
7. Drug evaluation: Vilazodone--a combined SSRI and 5-HT1A partial agonist for the treatment of depression.
de Paulis T
IDrugs; 2007 Mar; 10(3):193-201. PubMed ID: 17351874
[TBL] [Abstract][Full Text] [Related]
8. Vilazodone approved for major depression.
Traynor K
Am J Health Syst Pharm; 2011 Mar; 68(5):366. PubMed ID: 21330672
[No Abstract] [Full Text] [Related]
9. Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression.
Khan A
Expert Opin Investig Drugs; 2009 Nov; 18(11):1753-64. PubMed ID: 19764890
[TBL] [Abstract][Full Text] [Related]
10. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?
Dawson LA
Expert Opin Drug Discov; 2013 Dec; 8(12):1529-39. PubMed ID: 24195711
[TBL] [Abstract][Full Text] [Related]
11. Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Hughes ZA; Starr KR; Langmead CJ; Hill M; Bartoszyk GD; Hagan JJ; Middlemiss DN; Dawson LA
Eur J Pharmacol; 2005 Mar; 510(1-2):49-57. PubMed ID: 15740724
[TBL] [Abstract][Full Text] [Related]
12. Vilazodone: a novel antidepressant.
Choi E; Zmarlicka M; Ehret MJ
Am J Health Syst Pharm; 2012 Sep; 69(18):1551-7. PubMed ID: 22935937
[TBL] [Abstract][Full Text] [Related]
13. Vilazodone hydrochloride, a combined SSRI and 5-HT1A receptor agonist for major depressive disorder.
Guay DR
Consult Pharm; 2012 Dec; 27(12):857-67. PubMed ID: 23229074
[TBL] [Abstract][Full Text] [Related]
14. Vilazodone: in major depressive disorder.
Frampton JE
CNS Drugs; 2011 Jul; 25(7):615-27. PubMed ID: 21699273
[TBL] [Abstract][Full Text] [Related]
15. Vilazodone: a new treatment option for major depressive disorder.
Owen RT
Drugs Today (Barc); 2011 Jul; 47(7):531-7. PubMed ID: 22013560
[TBL] [Abstract][Full Text] [Related]
16. Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.
Heinrich T; Böttcher H; Schiemann K; Hölzemann G; Schwarz M; Bartoszyk GD; van Amsterdam C; Greiner HE; Seyfried CA
Bioorg Med Chem; 2004 Sep; 12(18):4843-52. PubMed ID: 15336263
[TBL] [Abstract][Full Text] [Related]
17. Vilazodone for the treatment of major depressive disorder.
Iranikhah M; Wensel TM; Thomason AR
Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
[TBL] [Abstract][Full Text] [Related]
18. Vilazodone: another novel atypical antidepressant drug.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2011 Mar; 49(3):19-22. PubMed ID: 21323263
[TBL] [Abstract][Full Text] [Related]
19. Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist.
Page ME; Cryan JF; Sullivan A; Dalvi A; Saucy B; Manning DR; Lucki I
J Pharmacol Exp Ther; 2002 Sep; 302(3):1220-7. PubMed ID: 12183683
[TBL] [Abstract][Full Text] [Related]
20. [Antidepressants, stressors and the serotonin 1A receptor].
Kirilly E; Gonda X; Bagdy G
Neuropsychopharmacol Hung; 2015 Jun; 17(2):81-9. PubMed ID: 26192901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
